92 related articles for article (PubMed ID: 32886721)
1. Multi-Epitope-Based Vaccines for Colon Cancer Treatment and Prevention.
Corulli LR; Cecil DL; Gad E; Koehnlein M; Coveler AL; Childs JS; Lubet RA; Disis ML
Front Immunol; 2021; 12():729809. PubMed ID: 34526999
[TBL] [Abstract][Full Text] [Related]
2. T Cell Activating Thermostable Self-Assembly Nanoscaffold Tailored for Cellular Immunity Antigen Delivery.
Zhang J; Yang J; Li Q; Peng R; Fan S; Yi H; Lu Y; Peng Y; Yan H; Sun L; Lu J; Chen Z
Adv Sci (Weinh); 2023 Sep; 10(26):e2303049. PubMed ID: 37395451
[TBL] [Abstract][Full Text] [Related]
3. Screening for Cervical Cancer.
Eun TJ; Perkins RB
Med Clin North Am; 2020 Nov; 104(6):1063-1078. PubMed ID: 33099451
[TBL] [Abstract][Full Text] [Related]
4. From the Infection to the Immunotherapy in Cervical Cancer: Can We Stop the Natural Course of the Disease?
Luvero D; Lopez S; Bogani G; Raspagliesi F; Angioli R
Vaccines (Basel); 2020 Oct; 8(4):. PubMed ID: 33050484
[TBL] [Abstract][Full Text] [Related]
5. The Chemokine CXCL14 as a Potential Immunotherapeutic Agent for Cancer Therapy.
Giacobbi NS; Mullapudi S; Nabors H; Pyeon D
Viruses; 2024 Feb; 16(2):. PubMed ID: 38400076
[TBL] [Abstract][Full Text] [Related]
6. A broadly protective vaccine against cutaneous human papillomaviruses.
Mariz FC; Balz K; Dittrich M; Zhang Y; Yang F; Zhao X; Bolchi A; Ottonello S; Müller M
NPJ Vaccines; 2022 Oct; 7(1):116. PubMed ID: 36216845
[TBL] [Abstract][Full Text] [Related]
7. Enhanced immunogenicity of a positively supercharged archaeon thioredoxin scaffold as a cell-penetrating antigen carrier for peptide vaccines.
Cavazzini D; Spagnoli G; Mariz FC; Reggiani F; Maggi S; Franceschi V; Donofrio G; Müller M; Bolchi A; Ottonello S
Front Immunol; 2022; 13():958123. PubMed ID: 36032169
[TBL] [Abstract][Full Text] [Related]
8. Synergistic effects of exosomal crocin or curcumin compounds and HPV L1-E7 polypeptide vaccine construct on tumor eradication in C57BL/6 mouse model.
Abbasifarid E; Bolhassani A; Irani S; Sotoodehnejadnematalahi F
PLoS One; 2021; 16(10):e0258599. PubMed ID: 34648579
[TBL] [Abstract][Full Text] [Related]
9. The application of CRISPR/Cas9 system in cervical carcinogenesis.
Gao C; Wu P; Yu L; Liu L; Liu H; Tan X; Wang L; Huang X; Wang H
Cancer Gene Ther; 2022 May; 29(5):466-474. PubMed ID: 34349239
[TBL] [Abstract][Full Text] [Related]
10. RG1-VLP and Other L2-Based, Broad-Spectrum HPV Vaccine Candidates.
Huber B; Wang JW; Roden RBS; Kirnbauer R
J Clin Med; 2021 Mar; 10(5):. PubMed ID: 33802456
[TBL] [Abstract][Full Text] [Related]
11. Minor Capsid Protein L2 Polytope Induces Broad Protection against Oncogenic and Mucosal Human Papillomaviruses.
Pouyanfard S; Spagnoli G; Bulli L; Balz K; Yang F; Odenwald C; Seitz H; Mariz FC; Bolchi A; Ottonello S; Müller M
J Virol; 2018 Feb; 92(4):. PubMed ID: 29212932
[TBL] [Abstract][Full Text] [Related]
12. Broad Neutralization Responses Against Oncogenic Human Papillomaviruses Induced by a Minor Capsid L2 Polytope Genetically Incorporated Into Bacterial Ferritin Nanoparticles.
Yang F; Mariz FC; Zhao X; Spagnoli G; Ottonello S; Müller M
Front Immunol; 2020; 11():606569. PubMed ID: 33343580
[TBL] [Abstract][Full Text] [Related]
13. Broadly neutralizing antiviral responses induced by a single-molecule HPV vaccine based on thermostable thioredoxin-L2 multiepitope nanoparticles.
Spagnoli G; Pouyanfard S; Cavazzini D; Canali E; Maggi S; Tommasino M; Bolchi A; Müller M; Ottonello S
Sci Rep; 2017 Dec; 7(1):18000. PubMed ID: 29269879
[TBL] [Abstract][Full Text] [Related]
14. Developments in L2-based human papillomavirus (HPV) vaccines.
Schellenbacher C; Roden RBS; Kirnbauer R
Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616
[TBL] [Abstract][Full Text] [Related]
15. The current state of therapeutic and T cell-based vaccines against human papillomaviruses.
Yang A; Farmer E; Lin J; Wu TC; Hung CF
Virus Res; 2017 Mar; 231():148-165. PubMed ID: 27932207
[TBL] [Abstract][Full Text] [Related]
16. Combined prophylactic and therapeutic immune responses against human papillomaviruses induced by a thioredoxin-based L2-E7 nanoparticle vaccine.
Zhao X; Yang F; Mariz F; Osen W; Bolchi A; Ottonello S; Müller M
PLoS Pathog; 2020 Sep; 16(9):e1008827. PubMed ID: 32886721
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
